Effects of amifostine on radiation-induced cardiac damage

Acta Oncologica

Volumn 42, Issue 1, 2003, Pages 4-9

  Kruse, Jacqueline J C M ^a,b   Strootman, Erwin G ^a   Wondergem, Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IRRADIATION; RADIOTHERAPY; TISSUE;

CARDIAC DAMAGE;

CARDIOLOGY;

AMIFOSTINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA FLOW; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; FEMALE; FIBROSIS; HEART FUNCTION; HEART INJURY; HEART OUTPUT; HISTOLOGY; ISOLATED HEART; LUNG INJURY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; RAT; SCORING SYSTEM;

AMIFOSTINE; ANIMALS; CARDIAC OUTPUT; CORONARY CIRCULATION; DRUG EVALUATION; FEMALE; FIBROSIS; HEART; MYOCARDIUM; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0037223738     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/0891060310002168     Document Type: Article

References (42)

1. Gomez GA, Park JJ, Panahon AM, et al. Heart size and function after radiation therapy to the mediastinum in patients with Hodgkin's disease. Cancer Treat Rep 1983; 67: 1099-103.
2. Morgan GW, Freeman AP, McLean RG, Jarvie BH, Giles RW. Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985; 11: 1925-31.
3. Gustavsson A, Eskilsson J, Landberg T, et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol 1990; 1: 355-63.
4. Piovaccari G, Ferretti RM, Prati F, et al. Cardiac disease after chest irradiation for Hodgkin's disease: incidence in 108 patients with long follow-up. Int J Cardiol 1995; 24, 49: 39-43.
5. Gyenes G, Rutqvist LE, Liedberg A, Fornander T. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol 1998; 48: 185-90.
6. Fajardo LF, Stewart JR. Experimental radiation-induced heart disease. I. Light microscopic studies. Am J Pathol 1970; 59: 299-316.
7. Schultz-Hector S. Radiation-induced heart disease: review of experimental data on dose response and pathogenesis. Int J Radiat Biol 1992; 61: 149-60.
8. Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31: 1205-11.
9. Schultz-Hector S, Bohm M, Blochel A, et al. Radiation-induced heart disease: morphology, changes in catecholamine synthesis and content, beta-adrenoceptor density, and hemodynamic function in an experimental model. Radiat Res 1992; 129: 281-9.
10. Kruse JJCM, Zurcher C, Strootman EG, et al. Structural changes in the auricles of the rat heart after local ionizing irradiation. Radiother Oncol 2001; 58: 303-11.
11. Schultz-Hector S, Balz K. Radiation-induced loss of endothelial alkaline phosphatase activity and development of myocar dial degeneration. An ultrastructural study. Lab Invest 1994; 71: 252-60.
12. Wondergem J, van der Laarse A, van Ravels FJ, et al. In vitro assessment of cardiac performance after irradiation using an isolated working rat heart preparation. Int J Radiat Biol. 1991; 59: 1053-68.
13. Franken NA, Camps JA, van Ravels FJ, van der Laarse A, Pauwels EK, Wondergem J. Comparison of in vivo cardiac function with ex vivo cardiac performance of the rat heart after thoracic irradiation. Br J Radiol 1997; 70: 1004-9.
14. Lauk S. Endothelial alkaline phosphatase activity loss as an early stage in the development of radiation-induced heart disease in rats. Radiat Res 1987; 110: 118-28.
15. Jaenke RS, Robbins MEC, Bywaters T, Whitehouse E, Rezvani M, Hopewell JW. Capillary endothelium. Target site if renal radiation injury. Lab Invest 1993; 68: 369-405.
16. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 2000; 57: 113-88.
17. Grdina DJ, Kataoka Y, Murley JS. Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact 2000; 16: 237-79.
18. Dorr RT, Lagel KE. Anthracycline cardioprotection by amifostine (WR2721) and its active metabolite (WR-1065) in vitro. Proc Am Soc Clin Oncol 1994; 13: 435.
19. Damron TA, Spadaro JA, Margulies B, Damron LA. Dose response of amifostine in protection of growth plate function from irradiation effects. Int J Cancer 2000; 90: 73-9.
20. Krebs HA, Henseleit K. Untersuchungen uber die harnstoffbildung im tierkörper. Zeits für Zool Physiol Chem 1932; 210: 33-66.
21. Wondergem J, Franken NA, van der Laarse A, et al. Changes in cardiac performance and sympathetic stimulation during and after fractionated radiotherapy in a rat model. Radiother Oncol 1996; 38: 33-40.
22. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1976; 11: 447-55.
23. Pissarek M, Jänichen F, Blasig IE, et al. Cardioprotective potency of the radical scavenger S-2-(3 aminopropylamino)-ethylphosphorothioic acid in the post-ischaemic rat heart. Mol Cell Biochem 1995; 145: 121.
24. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart H. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 1999; 43: 227-32.
25. Liu JY, Brass D, Hoyle GW, Brody AR. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998; 153: 1839-47.
26. Travis EL, Parkins CS, Holmes SJ, Down JD, Fowler JF. WR-2721 protection of pneumonitis and fibrosis in mouse lung after single doses of x rays. Int J Radiat Oncol Biol Phys 1984; 10: 243-51.
27. Capizzi RL. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996; 23 (Suppl 8): 2-17.
28. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 1999; 26 (Suppl 7): 3-21.
29. Dorr RT. Cytoprotective agents for anthracyclins. Semin Oncol 1996; 23: 23-34.
30. Tannehill SP, Mehta MP. Amifostine and radiation: past, present and future. Semin Oncol 1996; 23: 69-77.
31. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Radioprotection of salivary glands by amifostine obtained in a rabbit animal model. Int J Radiat Oncol Biol Phys 1999; 45: 181-6.
32. Rojas A, Denekamp J. The influence of x-ray dose level on normal tissue protection by WR-2721. Int J Radiat Oncol Biol Phys 1984; 10: 2351-6.
33. Yuhas JM, Afzal SMF, Afzal V. Variation in normal tissue responsiveness to WR-2721. Int J Radiat Oncol Biol Phys 1984; 10: 1537-9.
34. Mori T, Nikado O, Sugahara T. Dephosphorylation of WR-2721 with mouse tissue homogenates. Int J Radiat Oncol Biol Phys 1984; 10: 1529-31.
35. Utley JA, Seaver N, Newton GL, Fahey RC. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 1984; 10: 1525-8.
36. Denekamp J, Rojas A. Radioprotection in vivo: cellular heterogeneity and fractionation. In: Simic M, Cerruti P, eds. Anticarcinogenesis and radioprotection. New York: Plenum, 1988. p. 421-30.
37. Stewart FA. Keynote address: modification of normal tissue response to radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 1989; 16: 1195-200.
38. Denekamp J, Rojas A, Stewart FA. Is radioprotection by WR-2721 restricted to normal tissues? In: Nygaard O, Simic M, eds. Radioprotectors and Anti-carcinogens. London: Academic Press Inc.; 1983. p. 665-79.
39. Durrand RE. Radioprotection by WR-2721 in vitro at low oxygen tensions. Br J Cancer 1983; 47: 387-92.
40. Denekamp J, Michael BD, Rojas A, Stewart FA. Radioprotection of mouse skin by WR-2721: the critical influence of oxygen tension. Int J Radiat Oncol Biol Phys 1982; 8: 531-4.
41. Chapman JD, Reuvers AP, Borsa J, Greenslock Cl. Chemical radioprotection and radiosensitization of mammalian cells growing in vitro. Radiat Res 1973; 56: 291-306.
42. Koch CJ, Howell RL. Combined radiation-protective and radio-sensitizing agent. Radiat Res 1981; 87: 265-83.